Cargando…
Timing of mTORI usage and outcomes in kidney transplant recipients
The introduction of mammalian target of rapamycin inhibitors (mTORi) as immunosuppressive agents has changed the landscape of calcineurin inhibitor-based immunosuppressive regimens. However, the timing of mTORi conversion and its associated outcomes in kidney transplantation have conflicting results...
Autores principales: | Lim, Lee-Moay, Kung, Lan-Fang, Kuo, Mei-Chuan, Huang, A-Mei, Kuo, Hung-Tien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847621/ https://www.ncbi.nlm.nih.gov/pubmed/33526978 http://dx.doi.org/10.7150/ijms.53655 |
Ejemplares similares
-
Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation
por: Chalabi-Dchar, Mounira, et al.
Publicado: (2021) -
Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review
por: Lian, Bi-Jun, et al.
Publicado: (2022) -
Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
por: Lim, Lee-Moay, et al.
Publicado: (2023) -
Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation
por: Lim, Lee-Moay, et al.
Publicado: (2022) -
Low serum calcium is associated with poor renal outcomes in chronic kidney disease stages 3–4 patients
por: Lim, Lee-Moay, et al.
Publicado: (2014)